Surgery, Gastroenterology and Oncology
Vol. 23, No. 4, Aug 2018
Surgical Margins and Lymphoid Infiltrate in Cholangiocarcinoma: When a Surgical Technique "Pushes" Tumor Biology to Provide Answer
Guido Torzilli, Luca Viganò
ORIGINAL PAPER, Aug 2018
Article DOI: 10.21614/sgo-23-4-250
Mass-forming cholangiocarcinoma (MFCCC) is a disease at increasing incidence (1,2). Liver resection (LR) is the standard treatment, while chemotherapy has a limited effectiveness (3,4).
Five-year survival rates after complete surgery range between 20 and 35% (5-9). Although surgery represents the unique curative treatment, the disease is characterized by low resectability and high post-surgical recurrences rates (1-4). To date, resectability is based on morphological features (number and size of lesions, vascular invasion), lymphnode metastases (N stage), and surgical radicality (5-12).
If the surgical technique could play a role in improving resectability, molecular markers rather than gross tumor features could aid in defining and clarifying further prognostic predictors helpful to better select and manage the patients accordingly. On a technical standpoint, the margin width, if negative, does not impact the outcome, while a positive margin (< 1 mm, R1 resection) is associated with higher local recurrence rate and worse survival (8-15).

However, our group disclosed subcategories of R1 with a different prognostic impact in the event of surgery for colorectal liver metastases, which allowed to increase their resectability (16-17). Whether these subcategories play a role for other liver tumors is still matter of debate. Prognosis prediction is of paramount relevance for patients management either for their selection, and for the therapeutic and follow up strategies.
Reliable molecular markers for MFCCC are still lacking as well as an adequate assessment of tumor biology. The analysis of lymphoid infiltrate (LI) may work in this direction. The oncologic impact of LI has been analyzed in several tumors.

The largest evidences concern colorectal cancers (18-23). Focusing on liver tumors, some data have been reported for HCC and colorectal liver metastases (24-32), while no prior study focused on MFCCC. These two aspects will be discussed in this review article.

Full Text Sources: Download pdf
Abstract:   Abstract EN
Views: 2337


Watch Video Articles


For Authors



Journal Subscriptions

Current Issue

Dec 2024

Supplements

Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)

e-ISSN: 2601 - 1700 (online)

ISSN-L: 2559 - 723X

Journal Abbreviation: Surg. Gastroenterol. Oncol.

Surgery, Gastroenterology and Oncology (SGO) is indexed in:
  • SCOPUS
  • EBSCO
  • DOI/Crossref
  • Google Scholar
  • SCImago
  • Harvard Library
  • Open Academic Journals Index (OAJI)

Open Access Statement

Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.

Journal Metrics

Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2



Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019

Creative Commons License
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/